Literature DB >> 23386415

Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.

S H Kim1, J G Kang, C S Kim, S-H Ihm, M G Choi, H J Yoo, S J Lee.   

Abstract

SU6656 is a small-molecule indolinone that selectively inhibits Src family kinase and induces death of cancer cells. The aim of the present study was to investigate the influence of SU6656 on cell survival and to assess the role of p21 and PI3K/Akt signaling in cell survival resulting from SU6656 treatment in anaplastic thyroid carcinoma (ATC) cells. When 8505C, CAL62, and FRO ATC cells were treated with SU6656, the viability of 8505C and CAL62 ATC cells decreased only after treatment with SU6656 at a dosage of 100 μM for 72 h, while the viability of FRO ATC cells decreased after treatment with SU6656 in a concentration- and time-dependent manner. Cell viability was not changed by pretreatment with the broad-spectrum caspase inhibitor z-VAD-fmk. Phospho-Src protein levels were reduced, and p21 protein levels were elevated. Phospho-ERK1/2 protein levels were multiplied without alteration of total ERK1/2, total Akt, and phospho-Akt protein levels. Regarding FRO ATC cells, the decrement of cell viability, the increment of cleaved PARP-1 protein levels, and the decrement of phospho-Src protein levels were shown in p21 siRNA- or LY294002-pretreated cells compared to SU6656-treated control cells. ERK1/2 siRNA transfection did not affect cell viability and protein levels of cleaved PARP-1, p21, and Akt. In conclusion, these results suggest that SU6656 induces caspase-independent death of FRO ATC cells by overcoming the resistance mechanism involving p21 and Akt. Suppression of p21 and Akt enhances the cytotoxic effect of SU6656 in FRO ATC cells. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23386415     DOI: 10.1055/s-0033-1333716

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  6 in total

1.  Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.

Authors:  S H Kim; J G Kang; C S Kim; S H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

2.  Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.

Authors:  S H Kim; J G Kang; C S Kim; S-H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2017-11-16       Impact factor: 4.256

3.  Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.

Authors:  Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Seong Jin Lee
Journal:  Endocrine       Date:  2019-05-17       Impact factor: 3.633

4.  Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.

Authors:  Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee
Journal:  Endocrine       Date:  2017-12-28       Impact factor: 3.633

Review 5.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30

6.  Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.

Authors:  Peng Li; Sarah Diab; Mingfeng Yu; Julian Adams; Saiful Islam; Sunita K C Basnet; Hugo Albrecht; Robert Milne; Shudong Wang
Journal:  Oncotarget       Date:  2016-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.